NewAge Publishes Major New Discovery on Blocking Spike Proteins From Binding to Human Cells

Rhea-AI Summary

NewAge (Nasdaq: NBEV) has announced a significant breakthrough in health science, isolating a mechanism that blocks spike proteins from binding to human cells. This discovery may enhance immune support and is backed by more than 200 patents and peer-reviewed studies. The company's Tahitian NONI® products, linked to notable health benefits, have generated over $7 billion in sales. The findings were presented at a prestigious conference, indicating strong academic validation. NewAge aims to partner with health organizations to leverage this breakthrough globally.

Positive

• Breakthrough discovery of a mechanism blocking spike proteins, enhancing immune support.
• Presentation of findings at a respected conference, demonstrating scientific credibility.
• Tahitian NONI® products with over $7 billion in sales, indicating strong market demand.

Negative

• None.

DENVER, Oct. 07, 2021 (GLOBE NEWSWIRE) -- NewAge, Inc. (Nasdaq: NBEV), the Colorado-based organic and healthy products company, today announced that it has discovered and isolated the mechanism of action to block spike proteins from binding to cells in the human body.   The Company believes the discovery to be of major significance and intends to both leverage the science within its own portfolio and to also partner with other medical, research, or pharma companies and health systems to enable the benefits of the discovery to become more broadly available to consumers worldwide.

NewAge has discovered what it believes to be breakthrough science in the pursuit of health and the strengthening of people’s immunity. A paper reporting the findings has been posted at the Center for Open Science. The company’s abstract, “Anti-viral properties of Morinda citrifolia (NONI®) fruit juice” was also recently presented during the Functional Foods and Coronavirus Disease (COVID-19) session of the 29th International Conference of the Functional Food Center, significant because of the academic peer-review required to verify the soundness of the scientific research.  The conference hosted experts in medicine and biology and industry to discuss the usage of bioactive compounds for immune support and health.

Brett West, Chief Scientist at NewAge, commented, “We have more than 200 patents, cooperative research studies, and peer-reviewed papers on NewAge’s Tahitian NONI® (NONI) products and this new discovery not just adds to the body of research, but brings our insights into the benefits for consumers to an important new level. We have now been able to measure the ability of NONI and its major phytonutrients to block the binding of the spike proteins to cellular membranes. Using enzyme-linked immunosorbent assays (ELISA) to detect the competitive inhibition of spike protein to Angiotensin II Receptors (ACE-2) binding by NONI, NewAge scientists uncovered that NONI inhibited the ability of the spike proteins to bind ACE-2 by approximately 70%.”

Noni fruit comes from remote outlying areas in the islands of Polynesia and has been used as natural medicine by Tahitians for centuries. Noni fruit from Tahiti is one of the world’s richest sources of antioxidants, and NewAge sources almost all available noni fruit from that region ir direct partnership with growers from farm to bottle. Tahitian NONI® has generated more than $7 Billion in worldwide sales to already rank as one of the world leaders in natural nutritional supplement sales.   A study conducted by university researchers in China demonstrated that consumption of NONI® promoted a decrease in oxidative stress in cells by 18%, helped improve NK cell activity by >30% and helped increase Interleukin-2 (IL2) by 32% (that supports activation of NK Cells). A separate group of Japanese researchers found that these increases were due to a group of phytonutrients named iridoids, of which noni is a unique food source. In another study, Tahitian Noni juice also helps increase CD4+/CD8+ T-cell ratio, a marker of immune system health. Additional information can be found in the US Nat’l Library of Medicine in the NIH indexed publication https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920423/ and in the NIH indexed publication https://pubmed.ncbi.nlm.nih.gov/24868850/.

"Presenting at the FCC conference is great recognition for NewAge and a really big deal,” commented Deanna Latson, Chief Product Officer at NewAge. “An even bigger deal, is our new discovery, one of the magnitude that would normally be expected to come from major pharma companies, research institutes or health systems. The amount of research and scientific data that goes into being able to present findings of this nature is a an arduous hurdle, and the significance of NewAge’s new discovery and the impact it may have on immune health has never been more critical and timely given today’s environment.”

About NewAge, Inc.
NewAge is a purpose-driven firm dedicated to inspiring the planet to Live Healthy™. Colorado-based NewAge commercializes a portfolio of organic and healthy products worldwide through primarily a direct-to-consumer (D2C) route to market distribution system across more than 75 countries. The company competes in three major category platforms including health and wellness, inner and outer beauty, and nutritional performance and weight management — leading a network of more than 400,000 exclusive independent Brand Partners, empowered with the leading social selling tools and technology available worldwide.

More information on the Company can be found at www.NewAge.com.

Safe Harbor Disclosure
This press release contains forward-looking statements that are made under the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statement reflecting management's expectations regarding future results of operations, economic performance, and financial condition. The forward-looking statements are based on the assumption that operating performance and results will continue in line with historical results. Management believes these assumptions to be reasonable, but there is no assurance they will prove to be accurate. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially. NewAge competes in a rapidly growing and transforming industry, and risk factors, including those disclosed in the Company's filings with the Securities and Exchange Commission, might affect the Company's operations. Unless required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements.

For investor inquiries about NewAge please contact:

NewAge Investor Relations:
BPC Financial Marketing
800 816 7361
ir@bpcfinancialmarketing.com

FAQ

What is NewAge's recent discovery regarding spike proteins?

NewAge has isolated a mechanism that blocks spike proteins from binding to human cells, a significant breakthrough for immune support.

How significant is the discovery announced by NewAge on October 7, 2021?

The discovery is considered major, potentially impacting immune health and is supported by extensive research.

What are the market implications of NewAge's announcement?

The discovery may lead to partnerships with medical and research entities, enhancing consumer access to health benefits.

What product has contributed to NewAge's over $7 billion in sales?

Tahitian NONI® products have generated more than $7 billion in sales, establishing NewAge as a leader in the natural nutritional supplement market.

What academic validation supports NewAge's claims?

The discovery was presented at the International Conference on Functional Foods, requiring peer-reviewed verification.